Active Ingredient History
Vismodegib (trade name Erivedge) is a drug for the treatment of basal-cell carcinoma (BCC). It was approved by FDA on January 30, 2012 and by the European Commission on 12 July 2013, for the treatment of adult patients with symptomatic metastatic BCC, or locally advanced BCC inappropriate for surgery or radiotherapy. The drug is also undergoing clinical trials for metastatic colorectal cancer, small-cell lung cancer, advanced stomach cancer, pancreatic cancer, medulloblastoma and chondrosarcoma as of June 2011. The substance acts as a cyclopamine-competitive antagonist of the smoothened receptor (SMO) which is part of the hedgehog signaling pathway. The Hedgehog signaling pathway plays an important role in tissue growth and repair; aberrant constitutive activation of Hedgehog pathway signaling and uncontrolled cellular proliferation may be associated with mutations in the Hedgehog-ligand cell surface receptors PTCH and SMO. SMO inhibition causes the transcription factors GLI1 and GLI2 to remain inactive, which prevents the expression of tumor mediating genes within the hedgehog pathway. This pathway is pathogenetically relevant in more than 90% of basal-cell carcinomas. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Basal Cell Nevus Syndrome (Phase 2)
Bile Duct Neoplasms (Phase 2)
Biliary Tract Neoplasms (Phase 2)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Chondrosarcoma (Phase 2)
Chondrosarcoma, Clear Cell (Phase 2)
Chondrosarcoma, Mesenchymal (Phase 2)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 2)
Dermatofibrosarcoma (Phase 1/Phase 2)
Diffuse Intrinsic Pontine Glioma (Phase 2)
Endometrial Neoplasms (Phase 2)
Esophageal Neoplasms (Phase 2)
Fibrosarcoma (Phase 1/Phase 2)
Gastrointestinal Neoplasms (Phase 2)
Gastrointestinal Stromal Tumors (Phase 1/Phase 2)
Genetic Diseases, Inborn (Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Gliosarcoma (Phase 2)
Healthy Volunteers (Phase 1)
Hedgehog Proteins (Phase 1/Phase 2)
Hemangioendothelioma (Phase 1/Phase 2)
Idiopathic Pulmonary Fibrosis (Phase 2)
Intestinal Neoplasms (Phase 1/Phase 2)
Kidney Diseases (Phase 1/Phase 2)
Kidney Neoplasms (Phase 2)
Leiomyosarcoma (Phase 1/Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Liposarcoma (Phase 1/Phase 2)
Liver Neoplasms (Phase 2)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Medulloblastoma (Phase 2)
Melanoma (Phase 2)
Meningioma (Phase 2)
Multiple Myeloma (Phase 2)
Mutation (Phase 2)
Myelodysplastic Syndromes (Phase 2)
Neoplasm Metastasis (Phase 4)
Neoplasms ()
Nerve Sheath Neoplasms (Phase 1/Phase 2)
Osteosarcoma (Phase 1/Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Primary Myelofibrosis (Phase 1/Phase 2)
Prostatic Neoplasms (Phase 2)
Rhabdomyosarcoma (Phase 1/Phase 2)
Sarcoma (Phase 1/Phase 2)
Sarcoma, Ewing (Phase 1/Phase 2)
Sarcoma, Kaposi (Phase 1/Phase 2)
Sarcoma, Synovial (Phase 1/Phase 2)
Skin Neoplasms (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 2)
Thyroid Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
